chemical-biology-2020 banner-min .jpg

PROFESSIONAL EVENT SPEAKERS


Saminathan Malaysia.jpg

Dr. Saminathan Kayarohanam

Geomatika University College, Malaysia

Cluster Dean / Associate Professor Head, Department of Pharmaceutical Education, Geomatika University College, Kuala Lumpur, WP Kuala Lumpur, Malaysia. He received the PhD in Department of Phytochemistry, The Open International University for Complementary Medicines – Srilanka in 2012. He established new drug information centre in Malaysia (GUC).

Major area of interests include Phytochemistry, Pharmaceutical Science and Pharmacy practice

parathasarathi-das-chemical-biology-1.jpg

Dr. Parthasarathi Das

IIT-ISM Dhanbad, India

Dr. Partha Sarathi Das has been chosen to receive the prestigious CRSI Bronze Medal for his incomparable research contribution in the field of Chemistry by Chemical Research Society of India (CRSI). Dr Das, having his Post-Doctoral degree and experiences from reputed institutions like Harvard University, USA, Tohoku University, Japan and RWTH-Aachen, Germany, started his career as Senior Scientist @ Dr. Reddy’s Laboratories, Hyderabad. He has had more than 10 years of industry experience before joining as Senior Scientist at Integrative Medicine Centre of (CSIR) at Jammu.

Currently, he is serving as Associate Professor in the Department of Applied Chemistry at IIT(ISM) Dhanbad since December, 2017.

His areas of expertise are Catalysis and Heterocyclic Chemistry, Medicinal Chemistry and Drug Discovery, Total Synthesis of Biological Active Molecules, Affordable Synthesis of FDA-Approved Drug, Synthesis and Characterization of Drug Impurities.

https://www.iitism.ac.in/pdfs/faculty/dr.parthasarathidas.pdf

LAM-Chemical-Conferences.jpg

Prof.Patrick Lam

Distinguished professor; Blumberg Institute, USA

Dr. Lam is a medicinal chemistry and drug discovery consultant. He currently collaborates with Blumberg scientists in terms of drug discovery and jointly supervises Blumberg chemistry postdocs and visiting scientists.

Dr. Lam has 30 years of extensive experience in innovation in structure-based drug design, ADME, focused libraries, molecular recognition and nucleic acid therapeutics to deliver biopharma clinical candidates with novel profiles. He is responsible for the discovery of a total of eight clinical candidates. At Bristol Myers Squibb, Dr Lam was the group leader/co-inventor responsible for the discovery of  Eliquis®/Apixaban, a novel Factor Xa anticoagulant recently launched on the market. Eliquis® is projected by analysts to be a transformational medicine with “blockbuster” sales potential. Eliquis® was chosen as the “Best New Medicine of 2012” by Med Ad News. He and his team were awarded 2015 American Chemical Society Heroes of Chemistry Award for the discovery of Eliquis®. Dr Lam is also the inventor of the novel cyclic urea class of HIV protease inhibitors that resulted in Mozenavir/DMP450. In the Phase II clinical trial, Mozenavir was shown to be as efficacious as Merck’s Crixivan, but without the lipodystrophy side effect of Crixivan.

In recent years, he has been involved with antivirals (HBV capsid, surface antigen and cccDNA inhibitors, Dengue Fever inhibitors, HIV-DC-SIGN blockers), antithrombotics (FXIa and FXa inhibitors as anticoagulants; P2Y1 and PAR4  antagonists as antiplatelet agents), a PCSK9 antisense oligonucleotide (ASO) therapeutics, prodrugs and carbohydrates.

In the organic chemistry area, he is internationally known as the co-discoverer of the powerful copper-promoted Chan-Lam Coupling Reaction, a complementary reaction to the Nobel-prize winning Suzuki-Miyaura Coupling Reaction. Dr. Lam has authored 98 papers/reviews/book chapters, invented 36 patents/patent applications and presented 110 invited seminars worldwide.

Dr.Toyonobu Usukii.jpg

Dr.Toyonobu Usukii

Doctor

Toyonobu Usuki obtained his B.S., M.S., and Ph.D. degrees in chemistry under the supervision of Professor Masahiro Hirama and Professor Masayuki Inoue from Tohoku University, Sendai, Japan, in 2000, 2002, and 2005, respectively. After postdoctoral studies in the laboratory of Professor Koji Nakanishi at the Department of Chemistry, Columbia University, New York, USA, from 2005 to 2007 as a JSPS Postdoctoral Fellow for Research Abroad, he joined the Department of Materials and Life Sciences, Sophia University, Tokyo, Japan, as an Assistant Professor (Principal Investigator) in 2008. Since 2013, he is an Associate Professor at the same university. His research interests include natural products chemistry, organic chemistry, medicinal chemistry, and bioorganic chemistry.

Gautam Sethi (1).jpg

Prof. Gautam Sethi

professor

Prof. Gautam Sethi joined the Department of Pharmacology, Yong Loo Lin School of Medicine, the National University of Singapore in 2008 as an Assistant Professor and was promoted to Associate Professor in 2015. 

Research: The focus of his research over the past few years has been to elucidate the mechanism (s) of activation of oncogenic transcription factors such as NF-kB/STAT3 by carcinogens and inflammatory agents and the identification of novel inhibitors of these proteins for prevention of and therapy for cancer. The findings of his research work have so far resulted in more than one hundred and fifty scientific publications in high impact factor peer reviewed journals and several international awards. He currently serves as an Academic Editor for PLOS, editorial board member of Scientific Reports, Pharmacological Research, BMC Cancer, Frontiers in Pharmacology, Frontiers in Oncology, and ad-hoc reviewer for several other international journals


Gopal-Natesan.jpg

Dr. Gopal Natesan

Director

Gopal Natesan has completed his Doctoral degree (PhD) in Pharmaceutical Chemistry from Hamdard University (Jamia Hamdard) New Delhi, India in 2000 and currently serving as Professor of Medicinal Chemistry & Deputy Dean of Research & Innovation and Students Affairs in Faculty of Pharmacy, MAHSA University, Kuala Lumpur, Malaysia. His research focuses on the synthesis of newer small chemical entities, quinazolinones heterocyclic pharmacophore and their preliminary screening in both in-vivo and in-vitro models mainly focusing on pain & inflammation and also for newer microbial agents. He has published >40 articles in indexed journals and presented >80 papers in conferences and invited speaker at international scientific meetings and conferences and serves as reviewer for several scientific international journals and also as Editorial/Advisory board of various journals.

Dr. Sundaram Arulmozhiraja-white.jpg

Dr. Sundaram Arulmozhiraja

Associate Professor,Rikkyo University,Japan

Sundaram Arulmozhiraja has over twenty years of research experience in computational chemistry/biology. He worked for various national institutes (National Institute for Environmental studies, National Institute of Materials and Chemical Research, National Institute for Materials Science) and universities (Kyoto University, Hokkaido University) in Japan as well as for the Australian National University in Australia. At present, he is working for the Rikkyo University in Japan as an Associate Professor. 

Facebook
Pinterest
Twitter
LinkedIn
blog Blog
Youtube